Aurinia Pharmaceuticals Inc
AUPHHealthcare|Biotechnology|Canada
$15.79
-0.81 (-4.88%)
DCF (FCF)
$1.77
Tangible Book
$4.31
Graham Number
$14.51
About
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Stock Price
+76.8%(1Y)
Pipeline Summary
20 total trials3
Phase 1
8
Phase 2
9
Phase 3
1
Phase 4
Completed: 14Terminated: 3Recruiting: 2Withdrawn: 1
Active Trials (2)
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
NCT07596901Myasthenia Gravis, Generalized
Phase 1Phase 2Recruiting
Enrollment: 81 participants
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NCT07611214Lupus Nephritis
Phase 4Recruiting
Enrollment: 150 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
TANG KEVINBUY
2026-06-02814,606 shares @ $15.29
TANG KEVINBUY
2026-03-03900,000 shares @ $14.1
TANG KEVINBUY
2025-08-051,300,000 shares @ $10.45
Keenan GregSELL
2025-08-0120,000 shares @ $10.5
Keenan GregSELL
2025-03-078,305 shares @ $8.23
Recent News
2026-07-06 13:00:14
2026-07-06 12:28:52
Data last updated: Jul 12, 2026, 07:42 PM